Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

  • Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.
     
  • Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion
     
  • Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US

Basel, September 6, 2018 – Novartis …

/by

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

  • Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
  • Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
  • Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …

/by

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

  • Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
  • Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
  • Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …

/by

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

  • Net sales grew 5% (cc[1], +7% USD) mainly driven by:
    • Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU
    • Entresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide
    • Oncology grew 10% (cc) driven by continued growth from Promacta/Revolade, Tafinlar + Mekinist and Jakavi, uptake of Kisqali and Kymriah and contribution from the AAA acquisition
  • Core[ …
/by

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

  • Net sales grew 5% (cc[1], +7% USD) mainly driven by:
    • Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU
    • Entresto sales more than doubled to USD 239 million, (+113% cc) driven by continued uptake worldwide
    • Oncology grew 10% (cc) driven by continued growth from Promacta/Revolade, Tafinlar + Mekinist and Jakavi, uptake of Kisqali and Kymriah and contribution from the AAA acquisition
  • Core[ …
/by

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

  • Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]
  • Switching from the reference medicine to Erelzi® (etanercept) did not impact efficacy and safety in patients with moderate to severe rheumatoid arthritis at 48 weeks[2]
  • Nearly 320 million people in Europe are expected to have limited access to disease-modifying anti-rheumatic medicines, underscoring the value of Zessly and Erelzi[3 …
/by

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

  • Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1]
  • Switching from the reference medicine to Erelzi® (etanercept) did not impact efficacy and safety in patients with moderate to severe rheumatoid arthritis at 48 weeks[2]
  • Nearly 320 million people in Europe are expected to have limited access to disease-modifying anti-rheumatic medicines, underscoring the value of Zessly and Erelzi[3 …
/by

Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

  • Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology
  • Positive CHMP opinion based on comprehensive analytical, preclinical and clinical data package that shows proposed biosimilar adalimumab matches reference medicine
  • This recommendation marks the fourth positive CHMP opinion for a Sandoz biosimilar within 18 months

Holzkirchen, June 1, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, …

/by

Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

  • Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology
  • Positive CHMP opinion based on comprehensive analytical, preclinical and clinical data package that shows proposed biosimilar adalimumab matches reference medicine
  • This recommendation marks the fourth positive CHMP opinion for a Sandoz biosimilar within 18 months

Holzkirchen, June 1, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, …

/by

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

  • European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine
  • Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems
  • Zessly is the third EC approval for a Sandoz biosimilar in 12 months …
/by